Impact of PIVC Length and Gauge on Catheter Indwell Time (NCT04344314) | Clinical Trial Compass
CompletedNot Applicable
Impact of PIVC Length and Gauge on Catheter Indwell Time
Australia40 participantsStarted 2020-08-31
Plain-language summary
This is a single-centre, open-label, multi-visit study design, in 40 healthy participants, randomized by gauge of peripheral intravenous catheter (PIVC) device into the lower arm cephalic vein of both arms.
The purpose of this study is to assess impact of catheter length and gauge on PIVC indwell time over a 72 hour period. This study will also evaluate the incidence of haemolysis using blood draws from the PIVC.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female or Male
* 18-65 years of age
* Not pregnant at time of recruitment within 48 hrs Day 1 procedures (self-reported)
* Normal coagulation results (prothrombin time 13-17 sec; activated partial thromboplastin time 27-37 sec)
* Normal platelet aggregation results for Adenosine DiPhosphate (ADP), Thrombin Receptor Activating Peptide (TRAP), and collagen induced maximal amplitude (\>70% amplitude over 6 mins)
* Target cephalic veins readily cannulatable (i.e., ≥ \~2.55 mm to obtain C/V ratio less than 45% as indicated by standard 52 of the Intraevenous Nursing Standards (INS) guidelines
* Able and willing to provide verbal and written consent
* Must be an Australian citizen with current Medicare card
Exclusion Criteria:
* History of pro coagulative state/condition (e.g. previous deep vein thrombosis
* Current hypertension (e.g., systolic \>139 OR diastolic \>89 mmHg)
* Currently on any anti-coagulant or platelet inhibitor medication. Use of NSAIDs and aspirin will be documented however not exclusionary.
* Hemophilia or any current or history of bleeding disorder or tendency
* Presence or report of current blood borne disease/infection (e.g. hepatitis, HIV, leukemia, lymphoma)
* Difficult vascular access (i.e., vein must be readily palpable and cannulatable - no less than \~2.55 mm diameter to maintain ≤45% C/V ratio) as indicated by standard 52 of the INS guidelines
* Allergy or sensitivity to chlorhexidine gluconate, isopropyl alcohol, latex, or skin…
What they're measuring
1
Patent Indwell Time Between PIVCs of Different Length and Gauge.